These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2110 related items for PubMed ID: 25661724

  • 1. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.
    Mol Pharm; 2015 Apr 06; 12(4):1105-20. PubMed ID: 25661724
    [Abstract] [Full Text] [Related]

  • 2. Growth of Metastatic Triple-Negative Breast Cancer Is Inhibited by Deep Tumor-Penetrating and Slow Tumor-Clearing Chemotherapy: The Case of Tumor-Adhering Liposomes with Interstitial Drug Release.
    Stras S, Howe A, Prasad A, Salerno D, Bhatavdekar O, Sofou S.
    Mol Pharm; 2020 Jan 06; 17(1):118-131. PubMed ID: 31825626
    [Abstract] [Full Text] [Related]

  • 3. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
    Godugu C, Doddapaneni R, Singh M.
    Colloids Surf B Biointerfaces; 2017 May 01; 153():208-219. PubMed ID: 28249200
    [Abstract] [Full Text] [Related]

  • 4. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W, Zhang Q.
    Int J Pharm; 2015 Apr 30; 484(1-2):16-28. PubMed ID: 25700543
    [Abstract] [Full Text] [Related]

  • 5. Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.
    Godugu C, Doddapaneni R, Safe SH, Singh M.
    Eur J Pharm Biopharm; 2016 Nov 30; 108():168-179. PubMed ID: 27586082
    [Abstract] [Full Text] [Related]

  • 6. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T, Prasad P, Cai P, He C, Shan D, Rauth AM, Wu XY.
    Acta Pharmacol Sin; 2017 Jun 30; 38(6):835-847. PubMed ID: 28216624
    [Abstract] [Full Text] [Related]

  • 7. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells.
    Pindiprolu SKSS, Chintamaneni PK, Krishnamurthy PT, Ratna Sree Ganapathineedi K.
    Drug Dev Ind Pharm; 2019 Feb 30; 45(2):304-313. PubMed ID: 30348020
    [Abstract] [Full Text] [Related]

  • 8. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.
    Oncol Rep; 2013 Jul 30; 30(1):413-8. PubMed ID: 23624870
    [Abstract] [Full Text] [Related]

  • 9. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
    Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y.
    Int J Pharm; 2012 Jul 01; 430(1-2):238-46. PubMed ID: 22465546
    [Abstract] [Full Text] [Related]

  • 10. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
    Pindiprolu SKSS, Krishnamurthy PT, Dev C, Chintamaneni PK.
    Chem Phys Lipids; 2021 Mar 01; 235():105033. PubMed ID: 33385372
    [Abstract] [Full Text] [Related]

  • 11. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.
    BMC Cancer; 2014 Nov 19; 14():847. PubMed ID: 25410881
    [Abstract] [Full Text] [Related]

  • 12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 13. Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer.
    Chaudhuri A, Naveen Kumar D, Kumar D, Kumar Agrawal A.
    Eur J Pharm Biopharm; 2024 Aug 01; 201():114386. PubMed ID: 38950717
    [Abstract] [Full Text] [Related]

  • 14. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T, Liu M, Luo H, Wu C, Tang X, Tang S, Hu P, Yan Y, Wang Z, Tu G.
    J Steroid Biochem Mol Biol; 2014 Sep 01; 143():392-403. PubMed ID: 24874276
    [Abstract] [Full Text] [Related]

  • 15. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
    Qu J, Zhang L, Chen Z, Mao G, Gao Z, Lai X, Zhu X, Zhu J.
    Drug Deliv; 2016 Nov 01; 23(9):3408-3416. PubMed ID: 27181462
    [Abstract] [Full Text] [Related]

  • 16. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 17. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization.
    Darabi F, Saidijam M, Nouri F, Mahjub R, Soleimani M.
    Biomed Res Int; 2022 Dec 09; 2022():6253978. PubMed ID: 35845934
    [Abstract] [Full Text] [Related]

  • 18. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
    Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X.
    Drug Deliv; 2016 Oct 09; 23(8):2720-2725. PubMed ID: 26203691
    [Abstract] [Full Text] [Related]

  • 19. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y, Li XQ, Duan JL, Bao CJ, Cui YN, Su ZB, Xu JR, Luo Q, Chen M, Xie Y, Lu WL.
    Int J Nanomedicine; 2019 Oct 09; 14():3645-3667. PubMed ID: 31190817
    [Abstract] [Full Text] [Related]

  • 20. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS, Lee A, Park YS.
    Theranostics; 2019 Oct 09; 9(3):837-852. PubMed ID: 30809312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 106.